The global tadalafil market is expected to grow at a considerable CAGR during the forecast period (2022-2028). Male sexual function disorders including impotence or erectile dysfunction-ED are treated with tadalafil, when used in conjunction with sexual stimulation, enables a man to get and maintain an erection by boosting blood flow to the penis. Additionally, tadalafil is a drug that is used to treat the signs and symptoms of prostate enlargement (benign prostatic hyperplasia-BPH). It helps to relieve BPH symptoms include having problems initiating a pee stream, having a weak stream, and needing to urinate frequently or urgently (including during the middle of the night). When tadalafil is taken, the smooth muscle in the prostate and bladder is thought to relax. 

Various growth methods, including as partnerships and collaborations, mergers and acquisitions, geographical development, and new product releases, are significantly adopted by the leading companies in the field to stay competitive in the market place. For instance, in March 2020, the launch dates for Tadalafil tablets (the branded product: Cialis) have been announced by Sawai Pharmaceutical Co., Ltd. The company has launched tadalafil tablets 10 mg CI, and tadalafil tablets 20 mg CI in March 2020. 

Additionally, growing use of drugs such as Sildenafil (Viagra), Vardenafil (Levitra, Staxyn), Avanafil (Stendra), among others that restrain the growth of the tadalafil market. The rising prevalence of erectile dysfunction mainly in Japan is a major element driving market growth. 

Impact of COVID-19 on Global Tadalafil Market.

The COVID-19 has benefited the tadalafil market. The COVID-19 infected persons were more than 5 times more likely to acquire ED (erectile dysfunction). Stress, worry, and sadness caused by COVID-19 can affect sexual health and contribute to ED. ED might be an indication of heart disease in its early stages. COVID-19 can affect heart health. This is due to the fact that it might create inflammation in many places of your body. This includes the heart, additionally, the adjacent blood capillaries and veins. These factors have increased the demand for tadalafil hence rise the growth of the tadalafil market globally.

Segmental Outlook 

The global tadalafil market is segmented based on type and application. Based on type, the market is sub-segmented into Purity: 98% and Purity: above 98%. Based on application the market is sub-segmented into erectile dysfunction, benign prostatic hyperplasia, others.

**The above-mentioned segments can be customized as per the requirements. 

Global Tadalafil Market Share by Product, 2021(%)

Purity: 98% Segment is holding a Prominent Share in the Global Tadalafil Market.

Based on type, purity: 98% is anticipated to hold a prominent share in the market. Further, Maiden Pharmaceutical Ltd. has made a Tadalafil (Adcirca) is a phosphodiesterase (PDE) inhibitor used to treat erectile dysfunction in men. During stimulation, it increases blood flow to the penis.

Regional Outlooks

The global tadalafil market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). North America is anticipated to hold lucrative share in the market owing to presence of market players coupled with increasing healthcare expenditure in the region. 

 **The market can be analyzed for a particular region or country level as per the requirement.

Global Tadalafil Market Growth, by Region 2022-2028

The Asia-Pacific is expected to witness the highest growth rate in the Global Tadalafil Market.

The global tadalafil market is anticipated to be dominated by the Asia-Pacific, and this trend is expected to continue during the forecast period.  Japan has the highest percentage of erectile dysfunction followed by China and US and Brazil having the lowest. According to data at the sixth Asian Congress of Sexology in Kobe, one in three Japanese men indicated they suffer from erectile dysfunction in a recent poll. With age, ED becomes more common: roughly 40% of men are affected at age 40, and over 70% of men are impacted at age 70.

Market Players Outlook

The major companies serving the global tadalafil market include Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co. Pvt. Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., and others. To enhance their market share, industry participants are adopting various strategies including mergers and acquisitions,  new launches, collaborations, and partnerships. For instance, the US Food and Drug Administration has given Alembic Pharmaceuticals NSE -0.06% approval for tadalafil pills, that are used to treat erectile dysfunction. The company's abbreviated new drug application (ANDA) for tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg has been approved by the US Food and Drug Administration (USFDA)

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global tadalafil market. Based on the availability of data, information related to new product launches, and relevant news is additionally available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.